$RXST News

RxSight Appoints Aziz Mottiwala President, CEO, Effective July 20, Succeeding Ron Kurtz

RxSight: Alcon Deal Reshapes The Long-Term Growth Story

B of A Securities Maintains Underperform on RxSight, Lowers Price Target to $6.5

RxSight, Inc. (RXST) Q2 2026 Earnings Call Transcript

Needham Reiterates Buy on RxSight, Maintains $11 Price Target

RxSight Sees Q2 Sales $32.000M-$34.000M vs $32.077M Est

RxSight Raises FY2026 Sales Guidance from $120.000M-$135.000M to $140.000M-$160.000M vs $129.250M Est

RxSight Sees Q2 Revenue Of $32M-$34M; Sees FY2026 Revenue Of $140M-$160M

RxSight, Inc. to Present at the Stifel 2026 Virtual Ophthalmology Forum

RxSight, Inc. (RXST) Presents at Bank of America Global Healthcare Conference 2026 Transcript

RxSight (RXST) Q1 2026 Earnings Transcript

RxSight, Inc. (RXST) Q1 2026 Earnings Call Transcript

RxSight, Inc. Q1 2026 Earnings Call Summary

Wells Fargo Maintains Equal-Weight on RxSight, Lowers Price Target to $9

Needham Maintains Buy on RxSight, Lowers Price Target to $11

RxSight Q1 Earnings Call Highlights

RxSight, Inc. (RXST) Reports Q1 Loss, Tops Revenue Estimates

RxSight (NASDAQ:RXST) Q1 2026 Results: Revenue Beats but Loss Widens Amid Cautious Market Reaction

RxSight, Inc. Reports First Quarter 2026 Results and Reiterates Full-Year Sales Outlook

RxSight Affirms FY2026 Sales Guidance of $120.000M-$135.000M vs $129.182M Est